aranidipine has been researched along with Hypertension in 11 studies
aranidipine: structure given in first source
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of aranidipine enteric-coated capsules on 24 h blood pressure and blood pressure variability (BPV) in patients with mild to moderate essential hypertension." | 9.17 | [The effects of aranidipine on ambulatory blood pressures in patients with mild to moderate essential hypertension]. ( Chen, L; Hua, Q; Jiang, H; Jiao, Y; Jin, H; Ke, YN; Sun, RH; Wang, Y; Yang, HY; Zheng, JT, 2013) |
| "To assess the efficacy and safety of aranidipine versus retard-released felodipine in Chinese patients with mild-to-moderate essential hypertension." | 9.17 | [Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension]. ( Chen, L; Jiao, Y; Jin, H; Ke, YN; Li, DY; Liu, MX; Wang, BY; Wang, L; Wang, Y; Yang, HY; Zhao, XL; Zheng, JT, 2013) |
| " Adverse events occurred at 11." | 6.77 | Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial. ( Chen, GL; Fan, CM; Li, HM; Li, YS; Lin, YZ; Pang, HM; Wang, L; Wu, SY; Yan, LR; Yu, J; Zhao, RP, 2012) |
| "To evaluate the effect of aranidipine enteric-coated capsules on 24 h blood pressure and blood pressure variability (BPV) in patients with mild to moderate essential hypertension." | 5.17 | [The effects of aranidipine on ambulatory blood pressures in patients with mild to moderate essential hypertension]. ( Chen, L; Hua, Q; Jiang, H; Jiao, Y; Jin, H; Ke, YN; Sun, RH; Wang, Y; Yang, HY; Zheng, JT, 2013) |
| "To assess the efficacy and safety of aranidipine versus retard-released felodipine in Chinese patients with mild-to-moderate essential hypertension." | 5.17 | [Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension]. ( Chen, L; Jiao, Y; Jin, H; Ke, YN; Li, DY; Liu, MX; Wang, BY; Wang, L; Wang, Y; Yang, HY; Zhao, XL; Zheng, JT, 2013) |
| "The effects of MPC-1304, a new calcium channel blocker, on blood pressure, serum lipoproteins, and carbohydrate metabolism were compared with those of atenolol in a group of patients with mild to moderate essential hypertension." | 5.08 | Effects of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins and serum carbohydrate metabolism in patients with essential hypertension. ( Arakawa, K; Kajiyama, G; Kusukawa, R; Mashiba, H; Nonaka, K; Sasaki, J; Shichiri, M; Sunaga, T; Tanaka, N, 1995) |
| " Adverse events occurred at 11." | 2.77 | Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial. ( Chen, GL; Fan, CM; Li, HM; Li, YS; Lin, YZ; Pang, HM; Wang, L; Wu, SY; Yan, LR; Yu, J; Zhao, RP, 2012) |
| "3-3 mg/kg), dose-response curves of the antihypertensive effect did not change and body weight gain was equal to that of the vehicle-treated group." | 1.28 | Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs. ( Haruno, A; Kanda, A; Miyake, H; Nagasaka, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (63.64) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L | 2 |
| Jiang, H | 1 |
| Hua, Q | 1 |
| Yang, HY | 2 |
| Zheng, JT | 2 |
| Jin, H | 2 |
| Jiao, Y | 2 |
| Wang, Y | 2 |
| Sun, RH | 1 |
| Ke, YN | 2 |
| Zhao, XL | 1 |
| Liu, MX | 1 |
| Wang, L | 2 |
| Wang, BY | 1 |
| Li, DY | 1 |
| Yan, LR | 1 |
| Li, YS | 1 |
| Chen, GL | 1 |
| Pang, HM | 1 |
| Wu, SY | 1 |
| Yu, J | 1 |
| Li, HM | 1 |
| Lin, YZ | 1 |
| Zhao, RP | 1 |
| Fan, CM | 1 |
| Hasegawa, K | 1 |
| Wakino, S | 1 |
| Kanda, T | 1 |
| Yoshioka, K | 1 |
| Tatematsu, S | 1 |
| Homma, K | 1 |
| Takamatsu, I | 1 |
| Sugano, N | 1 |
| Hayashi, K | 1 |
| Sasaki, J | 1 |
| Kajiyama, G | 1 |
| Kusukawa, R | 1 |
| Shichiri, M | 1 |
| Sunaga, T | 1 |
| Mashiba, H | 1 |
| Tanaka, N | 1 |
| Nonaka, K | 1 |
| Arakawa, K | 1 |
| Suzuki, S | 1 |
| Hashimoto, T | 1 |
| Kusano, S | 1 |
| Kapuku, K | 1 |
| Utsunomiya, T | 1 |
| Yano, K | 1 |
| Okumura, K | 2 |
| Ichihara, K | 2 |
| Nagasaka, M | 3 |
| Oda, N | 1 |
| Tajima, K | 1 |
| Miyoshi, K | 2 |
| Kanda, A | 3 |
| Nozawa, Y | 2 |
| Nakano, M | 1 |
| Miyake, H | 4 |
| Yamada, S | 1 |
| Uchida, S | 1 |
| Ohkura, T | 1 |
| Kimura, R | 1 |
| Kamei, H | 1 |
| Kanno, T | 1 |
| Haruno, A | 1 |
4 trials available for aranidipine and Hypertension
| Article | Year |
|---|---|
[The effects of aranidipine on ambulatory blood pressures in patients with mild to moderate essential hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2013 |
[Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension].
Topics: Antihypertensive Agents; Dihydropyridines; Double-Blind Method; Essential Hypertension; Felodipine; | 2013 |
Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; D | 2012 |
Effects of a new calcium channel blocker, MPC-1304, on blood pressure, serum lipoproteins and serum carbohydrate metabolism in patients with essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Apolipoprotein A-II; Apolipoproteins; Atenolol; Blood Glucose; | 1995 |
7 other studies available for aranidipine and Hypertension
| Article | Year |
|---|---|
Divergent action of calcium channel blockers on ATP-binding cassette protein expression.
Topics: Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Calcium Chan | 2005 |
Effect of a new calcium antagonist on hemodynamics at rest and exercise loading in patients with essential hypertension.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Exercise; Female; Hemodynamics; Hu | 1993 |
Calcium entry blocking activities of MPC-1304 and of its enantiomers and metabolites.
Topics: Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Dihydropyridines; Hypertension; In Vitro | 1993 |
Regional vascular effects of MPC-1304, a novel dihydropyridine derivative, in conscious normotensive and spontaneously hypertensive rats.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Heart Rate | 1996 |
Receptor occupation and pharmacokinetics of MPC-1304, a new Ca2+ channel antagonist, in spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Aorta; Binding, Competitive; Calcium Channel Blockers; Cerebral Corte | 1995 |
Renal effects of the calcium channel blocker aranidipine and its active metabolite in anesthetized dogs and conscious spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Blood Pressure; Calcium Channel Blockers; Creatinine; Dihydropyridine | 1998 |
Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Co | 1992 |